Skip to main content
Fig. 1 | Journal of Experimental & Clinical Cancer Research

Fig. 1

From: Ajuba inhibits hepatocellular carcinoma cell growth via targeting of β-catenin and YAP signaling and is regulated by E3 ligase Hakai through neddylation

Fig. 1

Depletion of Ajuba potentiates hepatocellular carcinoma cell growth in vitro and in vivo. a Negative correlation of mRNA expression of AJUBA and YAP in HCC Patient. b Immunoblot (IB) analysis of Ajuba and E-cadherin-associated protein levels in hepatocellular carcinoma (HCC) cell lines. GAPDH was used as a loading control. c Immunoblot analysis of the efficiency of stable knockdown of Ajuba in BEL7402 and HepG2 cells using GAPDH as a loading control. IB, immunoblot. d, e Analysis of the ability of Ajuba-depleted BEL7402 and HepG2 cells to form colonies (d) and spheroids in three dimensional (3D) cultures (e). Scale bar = 100 μm (×20), 200 μm (×10). f Grossly visible tumor size in Ajuba-depleted HCC cells vs control mice, measured on the day of sacrifice (after 5 weeks). g Enlarged tumor volumes in Ajuba-depleted HCC cells vs control mice, measured weekly. h, i Immunoblot assay (h) or immunohistochemistry assay (i) for expressions of Ajuba proteins in Ajuba shRNA or negative shRNA groups of xenograft model. Scale bar = 50 μm. Data are presented as Mean ± SEM from three independent experiments (*p < 0.05, **p < 0.01, ***p < 0.001)

Back to article page